Premium
Antitumor Effect of Irinotecan Hydrochloride (CPT‐11) on Human Renal Tumors Heterotransplanted in Nude Mice
Author(s) -
Miki Tsuneharu,
omura Norio,
Takaha Natsuki,
Nishimura Kazuo,
Kojitna Yasuyuki,
Sawada Masumi,
Okuyama Akihiko
Publication year - 1998
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1998.tb00369.x
Subject(s) - medicine , irinotecan , pharmacology , topoisomerase , kidney , renal cell carcinoma , drug , camptothecin , chemotherapy , cancer , in vitro , chemistry , colorectal cancer , biochemistry , organic chemistry
Background : There has been a paucity of antitumor drugs that are active against renal tumors. Irinotecan hydrochloride (CPT‐11), a DNA topoisomerase type 1 inhibitor, has demonstrated antitumor activity against human tumors, however, no antitumor effect of CPT‐11 on renal tumors has been reported. The antitumor effect of CPT‐11 was investigated on 2 human renal tumors (OUR‐10 and OUR‐20) heterotransplanted into nude mice. Methods : Tumor‐bearing nude mice were given daily intraperitoneal injections of multiple anticancer drugs suspended in 0.2 ml_ of phosphate‐buffered saline (PBS) 3 times at 3‐day intervals. Control mice were injected with 0.2 mL of PBS. The antitumor effects were evaluated by calculating the T/C ratio (treated tumors/controls) of the tumor volume. Results : Among the 10 anticancer drugs tested, 50 mg/kg of CPT‐11 showed an active antitumor effect on OUR‐20 (T/C ratio 34). However, all drugs tested on OUR‐10 failed to show antitumor activity. Conclusion: Since CPT‐11 was effective in 1 of 2 renal tumors examined without severe toxicity, this drug could be a candidate for chemotherapy of renal cell carcinoma.